Logo Logo Logo Logo Logo
  • Home
  • The Aging Crisis: Our Solution
  • Our Team
  • News
  • Pipeline
  • Home
  • The Aging Crisis: Our Solution
  • Our Team
  • News
  • Pipeline

02 Dec Pan-Biome Pharmaceuticals, Inc. provides update on its longevity research program: its compounds modulate inflammation, the gut microbiome, and increase lifespan of C. elegans by 30%

Posted at 10:07h in Recent News

...

Read More
Recent News
  • Pan-Biome Pharmaceuticals, a startup focused on age-related diseases and increasing human healthspan, reports positive results in a preclinical trial of colitis
  • Pan-Biome Pharmaceuticals, Inc. provides update on its longevity research program: its compounds modulate inflammation, the gut microbiome, and increase lifespan of C. elegans by 30%
  • Pan-Biome Pharmaceuticals, Inc reports positive results in preclinical trial of Inflammatory Bowel Disease: oral drug shows strong effect in modulating the gut microbiome
  • Derm-Biome Pharmaceuticals, Inc raises pre-seed funding, spins out new company focused on chronic inflammatory diseases
News Archives
  • April 2023
  • December 2021
  • February 2021
  • July 2020

Investor Inquiries: Gordon Eberwein
geberwein@derm-biome.com